A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabineopen access
- Authors
- Yi, Jun Ho; Park, Silvia; Kim, Jung Han; Won, Young-Woong; Lim, Do Hyoung; Han, Boram; Uhm, Jieun; Kim, Hae Su; Jung, Chul Won; Jang, Jun Ho
- Issue Date
- Jan-2018
- Publisher
- Impact Journals LLC
- Keywords
- Acute myeloid leukemia; Decitabine; Elderly patients
- Citation
- Oncotarget, v.9, no.5, pp.6607 - 6614
- Indexed
- SCOPUS
- Journal Title
- Oncotarget
- Volume
- 9
- Number
- 5
- Start Page
- 6607
- End Page
- 6614
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/2427
- DOI
- 10.18632/oncotarget.23823
- ISSN
- 1949-2553
- Abstract
- Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients. ? Yi et al.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/2427)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.